JP2022527108A5 - - Google Patents

Info

Publication number
JP2022527108A5
JP2022527108A5 JP2021558626A JP2021558626A JP2022527108A5 JP 2022527108 A5 JP2022527108 A5 JP 2022527108A5 JP 2021558626 A JP2021558626 A JP 2021558626A JP 2021558626 A JP2021558626 A JP 2021558626A JP 2022527108 A5 JP2022527108 A5 JP 2022527108A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
sequence number
sense strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021558626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527108A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025125 external-priority patent/WO2020205473A1/en
Publication of JP2022527108A publication Critical patent/JP2022527108A/ja
Publication of JP2022527108A5 publication Critical patent/JP2022527108A5/ja
Pending legal-status Critical Current

Links

JP2021558626A 2019-03-29 2020-03-27 Kras関連疾患または障害の治療のための組成物及び方法 Pending JP2022527108A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826121P 2019-03-29 2019-03-29
US62/826,121 2019-03-29
PCT/US2020/025125 WO2020205473A1 (en) 2019-03-29 2020-03-27 Compositions and methods for the treatment of kras associated diseases or disorders

Publications (2)

Publication Number Publication Date
JP2022527108A JP2022527108A (ja) 2022-05-30
JP2022527108A5 true JP2022527108A5 (cg-RX-API-DMAC7.html) 2023-04-04

Family

ID=70471081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021558626A Pending JP2022527108A (ja) 2019-03-29 2020-03-27 Kras関連疾患または障害の治療のための組成物及び方法

Country Status (13)

Country Link
US (1) US20220154189A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947681A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022527108A (cg-RX-API-DMAC7.html)
KR (1) KR20210145213A (cg-RX-API-DMAC7.html)
CN (1) CN113924365A (cg-RX-API-DMAC7.html)
AU (1) AU2020253823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018739A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134486A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002533A1 (cg-RX-API-DMAC7.html)
IL (1) IL286636A (cg-RX-API-DMAC7.html)
MX (1) MX2021011928A (cg-RX-API-DMAC7.html)
SG (1) SG11202110174PA (cg-RX-API-DMAC7.html)
WO (1) WO2020205473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
AU2022261124A1 (en) * 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
TW202339786A (zh) * 2022-01-21 2023-10-16 日商中外製藥股份有限公司 癌症之治療或預防用醫藥
CN121015887A (zh) * 2025-10-22 2025-11-28 天津市肿瘤医院(天津医科大学肿瘤医院) 预测胰腺癌对kras抑制剂耐药性的生物标志物及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
JPH06502300A (ja) 1990-08-03 1994-03-17 サノフィ 遺伝子発現の抑制のための化合物及び方法
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
WO1992005186A1 (en) 1990-09-20 1992-04-02 Gilead Sciences Modified internucleoside linkages
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
TW520293B (en) 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
ES2356342T3 (es) 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
AU2764801A (en) 2000-01-07 2001-07-24 University Of Washington Enhanced transport of agents using membrane disruptive agents
EP1299085B1 (en) 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005251691A1 (en) 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US7718193B2 (en) 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
CA2724014C (en) 2008-05-13 2016-09-13 University Of Washington Micellic assemblies
WO2009140421A2 (en) 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
WO2009140423A2 (en) 2008-05-13 2009-11-19 University Of Washington Targeted polymer bioconjugates
MX2010012238A (es) 2008-05-13 2011-04-11 Univ Washington Copolimeros dibloque y sus complejos con polinucleotidos destinados a introducirlos en celulas.
MX2010012237A (es) 2008-05-13 2011-04-28 Univ Washington Micelas para el suministro intracelular de agentes terapeuticos.
CA2734917A1 (en) 2008-08-22 2010-02-25 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
US20110281934A1 (en) 2008-11-06 2011-11-17 Phaserx, Inc. Micelles of hydrophilically shielded membrane-destabilizing copolymers
EP2364330B1 (en) 2008-11-06 2015-03-25 University Of Washington Multiblock copolymers
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
JP6010458B2 (ja) 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. 非対称二本鎖rnaによる特異的阻害のための、方法および組成物
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
RU2582235C2 (ru) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
JP2015529467A (ja) 2012-09-14 2015-10-08 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. 二本鎖rnaによるmycの特異的阻害に関する方法および組成物
EP2958998B1 (en) 2013-02-22 2017-12-27 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
CA3120574A1 (en) 2013-03-14 2014-09-25 Dicerna Pharmaceuticals, Inc. Process for formulating an anionic agent
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
US10858656B2 (en) * 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
WO2018098352A2 (en) * 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression

Similar Documents

Publication Publication Date Title
JP2025000818A (ja) 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
JP7007304B2 (ja) B型肝炎感染症治療用のPAPD5又はPAPD7のmRNA減少用核酸分子
KR102728481B1 (ko) Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법
JP2022502055A5 (cg-RX-API-DMAC7.html)
JP2022501040A5 (cg-RX-API-DMAC7.html)
CN114144423B (zh) 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症
JP2024535888A5 (cg-RX-API-DMAC7.html)
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
US20140004156A1 (en) Biological inhibitors of ror1 capable of inducing cell death
JP2005521393A5 (cg-RX-API-DMAC7.html)
JP2023539341A5 (cg-RX-API-DMAC7.html)
JP2024516356A5 (cg-RX-API-DMAC7.html)
JP2013504603A5 (cg-RX-API-DMAC7.html)
US11072795B2 (en) Antisense oligonucleotides
JP2024514880A5 (cg-RX-API-DMAC7.html)
RU2535993C2 (ru) Молекула rnai, нацеливающая тимидилатсинтазу и ее применение
JP2023516392A (ja) アプタマーおよびその使用
JP2009540857A (ja) Bcl−XL特異的siNAを用いる癌治療法
JP7493460B2 (ja) 有機化合物
TWI670064B (zh) 抗病毒劑及治療病毒感染之方法
JP5578498B2 (ja) 抗癌剤キット及び抗癌剤効果増強剤
US20100310579A1 (en) Method for inhibiting angiogenesis or for treatment of cancer
US20090087434A1 (en) Nfia in glial fate determination, glioma therapy and astrocytoma treatment
WO2022056117A1 (en) Nucleic acid-polypeptide compositions and uses thereof
WO2023040828A1 (zh) 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用